Search PubMed⌕ Search

Biomedical subjects

T W Barrowcliffe

Publications and source records attributed to T W Barrowcliffe.

At least 145 records · Page 8Linked to original sources

An international collaborative study establishing a reference preparation for Antithrombin III.

An international collaborative study involving 12 laboratories in 7 countries was carried out to establish a suitable reference preparation of antithrombin III (At III). The amount of At III present in two purified preparations, a freeze-dried normal plasma and local normal plasma pools was measured by clotting, immunological, and amidolytic assays. 120 assays were submitted of which 105 were accepted as valid for inclusion in subsequent analyses. Less laboratory to laboratory variation was found when At III was assayed in freeze-dried normal plasma, as compared to purified preparations of At III, and there was also less method to method variation when At III was measured in freeze-dried plasma. When measured as heparin co-factor activity, the two purified preparations contained only about half the level of At III found by immunoassay or progressive At III clotting assays. In contrast, the use of freeze-dried plasma provided results which showed excellent agreement between the various laboratories by all assays; accordingly, this material has been established by the World Health Organization as the International Reference Preparation for At III, with an assigned potency of 0.9 i.u. per ml.

Amides↗

Standardization of Factor VIII. I. Calibration of British Standards for Factor VIII clotting activity.

Calibration of successive British Standards for Factor VIII clotting activity against the International Standard (concentrate) has brought to light substantial discrepancies among laboratories and between assay methods. These discrepancies were less in assays of concentrate standards than in calibration of plasma standards. Standardization of reagents in the two-stage assays substantially improved agreement among laboratories using this method. Standardization of the phospholipid reagent and haemophilic substrate separately had little effect on variation among laboratories performing one-stage assays. Standardization of reagents did not alter the basic discrepancy (approximately 20%) between the one-stage and two-stage assay methods. Omission of the aluminium hydroxide adsorption step from the two-stage method reduced the discrepancy between the two methods to less than 10%. Discrepancies did not occur when one plasma standard was assayed against another. Improvements in the stability of VIII:C in freeze-dried plasma now make it feasible to establish a long-term plasma reference standard.

Adsorption↗

Standardization of Factor VIII. II. A British Standard for Factor VIII related antigen.

A collaborative study on factor VIII related antigen (VIII R:Ag) has been carried out, involving 11 laboratories in the U.K. Samples of two different freeze-dried plasmas were assayed against participants' own local standards by the Laurell electroimmunoassay method. There was reasonably good agreement on the relative potencies of the two freeze-dried plasmas, but there were considerable differences in the VIII R:Ag content of the plasma pools used as local standards, with values ranging from 83% to 129% of the mean. All participants agreed on the need for a standard for VIII R:Ag, and that the unit be defined by the mean of the local standards. Accordingly, freeze-dried plasma 66/355 was established as the 1st British Standard for factor VIII related antigen, with an assigned potency of 1.05 units per ampoule.

Antigens↗

In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods.

The recovery and half-life of VIII:C in the plasma of severely haemophilic patients was measured by one-stage and two-stage assays after injection of two Factor VIII concentrates (Hemofil, Hyland and Fraction I-O, Kabi). Plasma volumes were measured with an Evans' Blue technique, and both concentrates and post-infusion samples were measured against the same plasma standard. There was a highly significant difference in recoveries estimated by the two assay methods. The one-stage assays gave the most consistent results, in that the average recovery was 100%, whereas the two-stage assays gave only about 80% of the value expected from in vitro assays. There was no differences in recoveries between the two concentrates. The two-stage assays gave a slightly shorter half-life than the one-stage assays, and the half-life of Hemofil was also shorter than that of Fraction I-O.

Biological Assay↗

Anticoagulant activities of high and low molecular weight heparin fractions.

The anticoagulant activities of high and low molecular weight heparin fractions were measured by three assay methods, both in vitro, and after intravenous injection in volunteers. The low molecular weight (LMW) fraction had similar anti-Xa activity in vitro to the high molecular weight (HMW) fraction, but in APTT assays the HMW fraction was about twice as potent. After intravenous injection, the two fractions gave equal heparin levels by anti-Xa assays, but in APTT assays using synthetic substrate S-2222 gave about 20% lower levels than anti-Xa clotting assays for both heparins. Complete protamine neutralization of the post-injection heparin activity was found in APTT and synthetic substrate assays, but about 20% of the clotting anti-Xa effect could not be neutralized. Complete neutralization of the fractions by protamine was shown by all three assays in vitro. This non-neutralizable activity probably accounts for the difference between the anti-Xa clotting and synthetic substrate assays. Studies by crossed immunoelectrophoresis and affinity chromatography indicated that the antithrombin III binding properties of the two fractions were similar.

Adult↗

Absorption of factor VIII by aluminium hydroxide.

The absorption of factor VIII from gel filtration fractions, concentrates and plasma by aluminium hydroxide has been studied. Significant quantities of factor VIII could be removed when the protein concentration was low; the percentage absorbed increased with decreasing initial protein concentration. Factor VIII R:Ag and VIII:C were removed in parallel, but absorption of a high purity concentrate resulted in selective absorption of the lower molecular weight forms of factor VIII. Elution of the absorbed proteins gave a poor yield of VIII R:Ag, with no detectable VIII:C. Absorption of plasma showed no detectable loss of VIII R:Ag, but an apparent decrease of VIII:C of about 10%.

Absorption↗

Discrepancy between one-stage and two-stage assay of factor VIII:C.

Two methods (one-stage and two-stage) are commonly used for the assay of factor VIII clotting activity (VIII:C). We present collected data from seven separate studies of VIII:C assay which show that these methods do not give the same result when comparing concentrates and plasma. On average, two-stage assays detect 20% more VIII:C activity in concentrates as compared to plasmas than do one-stage assays.

Factor VIII↗

The effect of fatty-acid autoxidation products on blood coagulation.

Polyunsaturated fatty acids were allowed to autoxidise in air over 4 days. The water soluble oxidation products were extracted at daily intervals and tested for their effect on blood coagulation. After 1 day there was slight acceleration of the recalcification and RVV times, but from 2-4 days the extracts became increasingly inhibitory. The P.T. and P.T.T. were also inhibited. In the thrombin generation test the extracts delayed the appearance of thrombin, but the peak thrombin level was increased and its rate of decay was reduced. When added to phospholipid the extracts altered their coagulant activity. The presence of autoxidation products could account for some of the variable results obtained with different preparations of phospholipids.

Air↗